Italy EG STADA’s General Manager & Managing Director Italy, Salvatore Butti, explains the company’s strong heritage in generics, the solid presence it is developing in consumer healthcare with new acquisitions from GSK and Sanofi, and its biosimilar and specialties market inroads. In addition, he tells us about the STADA Health Report,…
USA Pharma companies have become vocal about social issues in recent years, championing access and affordability and launching initiatives to address diversity, but in the weeks since the United States’ Supreme Court’s overturn of the Roe v. Wade ruling on abortion the industry’s reaction has been far from consistent. While certain…
Italy Dompé’s Chief Operating Officer, Eriona Gjinukaj, responsible for creating the Italian mid-cap’s US affiliate, reveals the challenges and rewards of that experience and explains how she saw the company go from a primary care-focused Italian company to an internatonal biotech with an EMA and FDA-approved breakthrough therapy. I was lucky…
France Exor, led by Fiat brand heirs the Agnelli family, has signed a partnership agreement for an investment of EUR 833 million in the also family-owned French holding, Institut Mérieux, known for its diagnostic arm, BioMérieux. Under the new partnership, Exor will acquire a 10% shareholding in Institut Mérieux by way…
Italy UCB Italy’s Managing Director, Federico Chinni offeres his insights into UCB’s positioning and its new product launches, the first for the company in ten years. He also weighs in on Italy’s national Recovery and Resilience Plan and explains how the company was ready for digitalisation even before the pandemic. Our…
Global GSK has separated itself from its consumer healthcare business, newly named Haleon, home to brands such as Sensodyne and Advil. Now what? After underperforming in recent years, a few clinical trials fails and a resulting push for change from its investors, the breakup with its consumer healthcare arm was long-announced…
Italy GeneraLife, an in vitro fertilisation (IVF) clinic group with 14 clinics in Italy as well as in a number of other countries. The group’s Director of the Scientific Executive Committee, Dr Filippo Maria Ubaldi, spoke to us about the evolution of reproductive health, Italy’s alarmingly low birth rate and the…
Italy ENEA Tech and Biomedical is a foundation supervised by the Italian Ministry of Economic Development that aims to strengthen Italian R&D and the industrial transformation of the country’s biomedical sector. Its managing director, Marco Baccanti, outlines the organisation’s strategy to support and fund projects and analyses the current state of…
Italy Italy, Europe’s fourth largest pharma market at a size of EUR 23.446 billion, has a highly decentralised healthcare system, with the country’s 20 regions negotiating market access for medicines individually following central regulatory approval. This creates significant complexities for the representatives of Big Pharma looking to roll out their latest…
Spain Kyowa Kirin’s head of the South Europe cluster, Norberto Villarrasa, explains the Japanese company’s presence in Spain, its focus on rare diseases and onco-haematology, and comments on the challenges around access to rare disease treatments. In addition, the executive provides the company’s view on the potential and advantages of risk-sharing…
Italy Pierre Fabre Italy’s Charles-Henri Bodin highlights how the French firm’s offering has expanded far beyond its dermo-cosmetics heritage to today encompass a wide range of pharmaceuticals, including the key growth area of oncology. Bodin also outlines the importance of Italy – one of PF’s first international affiliates – to the…
Switzerland After a Moderna-Lonza production site and a Merck manufacturing facility were set up in western Switzerland, the country continues to attract big pharma capital with a CHF 200 million investment from Takeda. “Switzerland is a globally recognized hotspot for biopharma companies. As such, it naturally attracts investments. Our role is…
See our Cookie Privacy Policy Here